The Netherlands
PureIMS is a promising clinical stage pharmaceutical company established in 2014 in The Netherlands. With a focus on innovative inhaled therapies utilizing its proprietary dry powder inhaler, Cyclops®, the company aims to address systemic and respiratory diseases with high unmet medical needs. Its commitment is encapsulated in the slogan: “🫁 Improving the health and lives of patients through effective, safe and convenient inhaled drug delivery.”
The robust leadership team comprises seasoned life sciences executives with experience from mid-size and top-5 global pharma firms, as well as successful service providers, positioning the company well for growth and innovation. PureIMS is progressing with its lead candidate, Levodopa Cyclops®, for Parkinson’s disease, and has successfully marketed Colistin Cyclops® for cystic fibrosis under a named patient program.
Recent investment of €40.00K in September 2025 from investors such as Carduso Capital, IMDS, and LinesBridge Pharma underscores investor confidence. The venture offers a compelling opportunity in the Biotechnology and Life Sciences sectors.
